Impact of preoperative administration of finasteride on perioperative bleeding during transurethral vapor resection of the prostate

Djordje Argirovic ,
Djordje Argirovic
Aleksandar Argirovic
Aleksandar Argirovic

Published: 01.12.2010.

Biochemistry

Volume 27, Issue 2 (2011)

pp. 303-309;

https://doi.org/10.5937/matmed1102303a

Abstract

We investigated whether finasteride given before transurethral vapor resection (TUVRP) treatment has an impact on intra- and postoperative bleeding. Forty-two patients with diagnosis of benign prostatic hyperplasia (BPH) who had prostate volume (PV) > 30 mL underwent TUVRP: group A (n=21) received preoperatively finasteride 5 mg per day for median time of 7 months and group B (n=21) no finasteride. Preoperative evaluation include assessment of International Prostatic Symptom score (IPSS), Quality of Life (QoL), PV, maximum flow rate (Qmax) and postvoid residual (PVR). Patients mean age was 71.4± 2.1 vs 69.8 vs ± 3.4 years, respectively. Median PV was 55.5 ±21.2 vs 57.1 ±28.8 mL, respectively. Twenty-two (52%) patients had complete retention (29% vs 76%) (p<0.001). At baseline mean IPSS, QoL, Qmax and PVR were 18.1±5.9 vs 19.8±5.04, 3.3±1.7 vs 3.3±1.7, 8.1±4.4 vs 6.9±1.6 mL/s, and 146±106.9 vs 151.6±112.1 mL, respectively. The mean operation time was 59±16.8 vs 64±19.2 min, mean volume of irrigation fluid intraoperatively was 14.1±7.01 vs 15.2±8.1 L and postoperatively 7.0±2.1 vs 8.1 ±1.3 L, respectively. Mean blood loss was 312±85.9 vs 425±68.5 mL, respectively. The mean weight of resected tissue was 31.3±5.8 vs 30.75±8.4 gr, respectively. Mean duration of postoperative irrigation was 6.1 ± 4.7 vs 6.2 ±5.1 h, respectively. Thirty-six (85.7%) patients were discharged within 12 h postoperatively and the catheter is removed on 2.0±0.5 vs 2.5 ± 0.6 days, respectively. No patients received blood transfusion postoperatively. At 3 months postoperatively IPSS was 6.7±4.2 vs 5.2 ±2.01 (p<0.001), QoL 1.1±0.9 vs 1.1±0.7, Qmax 18.1±10.3 vs 17.5±8.1 mL/s (p<0.01) and PVR 41±46.1 vs 45±51.3 mL (p<0.05). The present study failed to demonstrate that preoperative treatment of BPH with finasteride did not have significant impact of perioperative bleeding at TUVRP.

Keywords

References

1.
Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol. 2003;(2):2–7.
2.
Jacobsen Sj G, Cj G, Hd. Oesterling jE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. arch Intern Med. 1995;477–81.
3.
Nickal Jc, Fradet Y, Rc B. Pommerville Pj, Perreauly jP, afridi sK et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PrOsPECT study). CMaj. 1996;1215–9.
4.
Roehrborn C, Mcnicholas T. The management of prostatic obstruction: haw to determine the best options? Eur Urol. 2003;(2):13–9.
5.
Mebust W, Holtgrewe H, Cockett, Peters P. Writing Comitee, the american Urological association. Transurethral prostatectomy: immediate and postoperatrive complications. Cooperative study of 13 participating institutions evaluating 3.885 patients. Urol. 1989;243–9.
6.
Gupta N, Kumar R. Transurethral vapor resection of prostate is a good alternative for prostate > 70 g. j Endourol. 2007;(12):1543–6.
7.
Carlin B. Bodner dr, spinnak jP, resnik MI. role of finasterid in treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate. 1997;180–2.
8.
Pj P, Miller M. The effect of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. Urol. 1995;1779–82.
9.
Sieber Pr, Rommel F, Huffnagle H, Ve, Harpster L. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. Urol. 1998;1232–3.
10.
Connell M. 5 alpha-reductase inhibitors. adv Protein Chem. 2001;143–8.
11.
Hagerty Ja, Ginsberg P, Harmon Jd H, Rc. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;684–7.
12.
Lund L, Kl EJ, Torring N, Nielsen Je. Impact of finasteride treatment of perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. scan j Urol Nephrol. 2005;160–2.
13.
Gj G, Bruskewitz R, Imperato-Mcginley J, Walsh P, Mcconnell Jd. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride study Group. N Engl j Med. 1992;1185–91.
14.
Stoner E. The clinical effects of 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride study Group. Urol. 1992;1292–302.
15.
H, Dr T, Foster M. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. Urol. 2002;2024–6.
16.
Bostwick Dg, Coner W, Denis L, Jones G, Murphy P, G. The association of benign prostatic hyperplasia and cancer of he prostate. Cancer. 1992;291–301.
17.
Patel A F, Gj, Guttierrez-Aceres J, Andrade-Perez F. Transurethral electrovaporization and vapour-rescetion of the prostate: an appraisal of possible electrosurgical after natives to regular loop resection. BjU Int. 2000;202–10.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners